Tian Zeng

513 citations
29 papers · 344 indexed · h-index 11
Topics
Cancer-related molecular mechanisms research (6 papers)Epigenetics and DNA Methylation (5 papers)Cancer Immunotherapy and Biomarkers (3 papers)
Partner nations
China

In The Last Decade

Tian Zeng

25 papers receiving 344 citations

Peers

Tian Zeng
Comparison fields: 5 of 84
  • Molecular Biology 184
  • Cancer Research 99
  • Oncology 90
  • Pulmonary and Respiratory Medicine 64
  • Immunology 48
Replace Нуршат Гайфуллин with:
Нуршат Гайфуллин Russia
Eejung Kim United States
Yujia Zhao China
Pia Hönscheid Germany
Gizem Gülfidan Türkiye
Justin K. Huang United States
Pau Badia-i-Mompel Germany
Xing Ren China
Xinwang Yuan China
Qiaojuan Jane Su Sweden
Tian Zeng relative to Нуршат Гайфуллин Russia Нуршат Гайфуллин's profile →
Citations per field
00.5×2.5×
Нуршат Гайфуллин · 1×
Citations per year

Countries citing papers authored by Tian Zeng

Since Specialization
Citations

This map shows the geographic impact of Tian Zeng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tian Zeng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tian Zeng more than expected).

Fields of papers citing papers by Tian Zeng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tian Zeng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tian Zeng. The network helps show where Tian Zeng may publish in the future.

Co-authorship network of co-authors of Tian Zeng

This figure shows the co-authorship network connecting the top 25 collaborators of Tian Zeng. A scholar is included among the top collaborators of Tian Zeng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tian Zeng. Tian Zeng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 0
3 0
4 8
5 2
6 44
7 28
8 0
9 15
10 9
11 18
12 12
13 2
14 3
15 37
16 18
17
LINC01170 promotes the progression of endometrial carcinoma by activating the AKT pathway.
7
18 31
19
Low PBRM1 identifies tumor progression and poor prognosis in breast cancer.
10
20 7

About Tian Zeng

Tian Zeng is a scholar working on Cancer Research, Molecular Biology and Pathology and Forensic Medicine, having authored 29 papers that have together received 344 indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (6 papers), Epigenetics and DNA Methylation (5 papers) and Cancer Immunotherapy and Biomarkers (3 papers). The work is most often cited by research in Cancer Research (99 citations), Oncology (90 citations) and Molecular Biology (184 citations). Tian Zeng has collaborated with scholars based in China. Frequent co-authors include Juan Zou, Zufan Zhang, Shaohui Sun, Yukun Li, Yukun Li, Wenchao Zhou, Juan Zou, Dan Mo, Guan Yang and Hui Ling. Their work appears in journals such as Analytical Chemistry, Scientific Reports and Analytica Chimica Acta.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026